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Abstract 
OBJECTIVE: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver 
disorder during pregnancy. ICP has been associated with morbidity but little is known 
about women’s long-term survival. Our aim was to determine whether ICP is associated 
with mothers’ long-term survival. 
STUDY DESIGN: The study population comprised 571 women with ICP in at least one 
pregnancy seen at Tampere University Hospital in Finland between 1969‒1988. The 
reference group comprised 1333 women: the previous and the following participant in the 
maternity ward diary. The data were obtained from Statistics Finland in March 2017 
containing deaths among the study participants between 1971‒2015. The follow-up time 
of the cohort was 27–46 years. The Kaplan-Meier method was used.  
RESULTS: Totally, 39 of the mothers with ICP (6.8%) and 111 of the reference group 
(8.3%) had died by the end of 2015 (p=0.267). The mean survival time of ICP women 
was 77.4 years and of the reference group 79.2 years (p=0.288). The mean survival time 
from labour in the ICP group was 45.0 years and in the reference group 44.8 years 
(p=0.259).  
CONCLUSIONS: Based on this study ICP does not seem to be associated with women’s 
survival. There is no need to follow-up ICP mothers' health because of the nonexistent 
risk of premature death. 
Keywords 
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Introduction 
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver condition which 
occurs most often in the late second or third trimester. The incidence is estimated to be 
between 0.2% and 2% and it varies geographically (1,2). The disease is more common in 
South Asia, South America and Scandinavia. The diagnosis requires the key symptom 
pruritus and a rise in serum bile acids and transaminases (1). During pregnancy the 
importance of ICP is related to its effects on the fetus (3). Fetal complications such as 
prematurity, fetal distress and stillbirth are associated with ICP (4,5). Within 48 hours of 
delivery the mother’s ICP symptoms usually resolve, and biochemical abnormalities 
resolve within 2−8 weeks (6). 
 
Genes, hormonal and environmental factors have an effect on the pathogenesis of 
intrahepatic cholestasis of pregnancy. Several gene mutations have an impact on its 
pathogenesis (7-14). Family clustering, the presence of ethnic and geographic variations, 
and mutations in gene coding for hepatobiliary transport proteins refer to genetic 
predisposition of ICP (1,2). Progesterone and estrogen seem to have an effect on the 
disease, and ICP patients have an altered steroidogenesis (15). Selenium deficiency and 
time of year may be involved in ICP’s pathogenesis (16-18). 
 
Recently, there has been growing interest in comorbidity associated with intrahepatic 
cholestasis of pregnancy. Increased risk for hepatobiliary diseases and cancers, some 
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autoimmune diseases, and cardiovascular diseases have been found (19-21). Women who 
have experienced ICP seem to have more gestational diabetes and pre-eclampsia than 
controls (22,23). The disease seems to be linked to hepatitis C infection (20, 24-26). ICP 
women was found to have a higher HCV viral load (26). 
 
Little attention has been paid to ICP women’s survival. The condition being the most 
common pregnancy related liver disease, it is important to know about ICP’s association 
regarding survival and public health. According to the writers’ knowledge, ICP mothers’ 
survival over such a long follow-up time has not been studied prior to this study. As ICP 
is associated with specific genetic profile and morbidity, the aim of this study was to 
determine whether there is an association between ICP and survival.  
Material and methods 
The study population comprised all ICP pregnancies at Tampere University Hospital, 
Finland, between 1969 and 1988. Patients with ICP were identified in the hospital 
discharge register using diagnosis codes. From 1969 to 1986, ICD-8 was used at Tampere 
University Hospital. Because ICD-8 did not include a precise code for ICP, we checked 
all the obstetric codes that might contain ICP: 637.9 Toxicosis NUD, 639.00 Pruritus, 
639.01 Icterus gravis, 639.09 Necrosis acuta et subacuta hepatis, and 639.98 Aliae 
definitae. Thereafter, we checked the written diagnosis behind the code, and if it referred 
to ICP, we included the case for further selection. ICD-9 was used between 1987 and 
1988, and it contained the appropriate codes 6467A Hepatosis gravidarum and 6467X 
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Hepatopathia alia. The diagnosis was verified from each patient record with the presence 
of the main symptom of itching and abnormal laboratory test results. At least one of the 
following was required: ASAT >35 U/l, ALAT >40 U/l, or bile acids 6 μmol/l or more. 
The study population comprised 687 ICP deliveries (27). The diagnosis of ICP was made 
in the special health care of University Hospital. 
 
The study population included some women with repeated ICP deliveries, and each of 
these women was studied as an individual case. The ICP group thus contained 575 
women. The reference group consisted of two women for each ICP delivery; the previous 
and the next women in the maternity ward diary. It was verified from the patient records 
that the women in the reference group were not diagnosed with ICP. Altogether, the 
reference group consisted of 1374 women. Four women were ruled out from the ICP 
cases because of a missing personal identity code, as were 41 women from the reference 
group. The final cohort comprised 571 women with ICP and 1333 women as a reference. 
Totally five hepatitis cases were diagnosed among the cohort until 2013, and two of them 
were hepatitis-C.   
 
We collected the cohort’s dates of death from Statistics Finland. The data contain all 
deaths to 2015. The follow-up time of the cohort was 27–46 years. The data were 
analysed using SPSS for Windows, version 22.0. The results were analysed with the 
Kaplan-Meier method. 
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The patients' consent was not required for this registry study. The study was approved by 
the Regional Ethics Committee of Tampere University Hospital (R02149) and the 
National Institute for Health and Welfare in Finland (THL/1051/5.05.00/2014). 
Results 
Totally, 39 of the mothers with ICP (6.8%) and 111 of the reference group (8.3%) had 
died by the end of 2015 (p=0.267). There were no differences between the groups 
regarding age at labour, at death and age of those who were living at the end of 2015 
(Table 1).   
The mean survival time from birth among ICP women was 77.4 years and among 
reference group 79.2 years, p-value being 0.288 (Figure 1). The mean survival time after 
labour in the ICP group was 45.0 years and in the reference group 44.8 years, p-value 
being 0.259 (Figure 2). 
Discussion 
Statistically significant differences were not found in the survival between the ICP and 
the reference groups.  
 
The cohort includes all ICP cases detected in Tampere University Hospital during 
1969−1988. Practically 100 percent of the deaths can be found in the data of Statistics 
Finland (28). The strength of our study is the long follow-up time, 27−46 years after 
delivery.  
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A weakness of the study is that it presents deaths at relatively early ages. Even a longer 
follow-up time is needed to examine whether ICP is associated with differences in 
survival among those who die older. The levels of bile acids and/or transaminases used 
for diagnosis of ICP were somewhat lower than more recent criteria and this can be 
regarded as a weakness of the study. The lack of knowledge of potential confounding 
factors such as body mass index can be considered weakness of the study. 
 
Previously ICP has been associated with age over 35 years (29). However, such an 
association was not found among this cohort. Thus, the cohort can be considered 
comparable with reference group regarding age. According to a questionnaire study with 
an excellent response rate, the groups were comparable regarding body mass index and 
education level (30). In the cohort, ICP women seem to have had fewer deliveries 
compared to the reference group (31). 
 
Within the same cohort, a questionnaire study showed that smoking was less common 
among the ICP patients than in the reference group (32). No differences regarding recent 
alcohol consumption or physical activity were found. Within the same cohort, the women 
with a history of ICP reported less high cholesterol and high blood pressure requiring 
medication (30). However, aforementioned diseases and health behaviour had no effect 
on survival. 
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Comorbidity has been recognized to be associated with ICP. In the questionnaire study 
made within the same cohort, ICP women reported more hypothyroidism and 
hepatobiliary diseases (30). Hepatobiliary diseases have shown to be associated with ICP 
in registry-based studies (19, 20) . Additionally, a registry-based study linked 
hypothyroidism and some other autoimmune diseases to ICP and found also an increased 
risk for cardiovascular diseases among ICP women (21). Moreover, gestational diabetes 
and pre-eclampsia have been associated with ICP (22, 23).  
 
The association between intrahepatic cholestasis of pregnancy and cancers has been 
studied. The questionnaire study suggested an association between ICP and breast cancer 
(30). In later registry-based studies, the linkage was not found (21,33). Instead, a 
connection between ICP and hepatobiliary cancer has been found (21). As a summary, 
ICP increases the woman’s risk for certain diseases. Although ICP is associated with 
certain comorbidity, the survival seems to be similar compared to controls. 
 
Hepatitis C has been associated with increased risk of occurrence of coronary 
atherosclerosis (34). Although hepatitis C has been associated with ICP (20,24,25), in our 
cohort there were no differences in the hepatitis C incidence between ICP women and the 
reference group. Thus, in our cohort hepatitis C comorbidity does not have an effect on 
survival.  
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ICP is associated with a certain genetic profile (1,2). The same profile may have an 
influence on the survival among ICP patients. Indeed, ICP itself might not have an effect 
on the survival but this specific genetic profile might have. This research brings a new 
insight for long-term aspects of ICP as studying survival over such a long follow-up time.  
 
During the follow-up time no statistically significant differences in the survival between 
the ICP and the reference group were found. Based on this study ICP does not seem to be 
associated with women’s survival in middle or younger age. This finding is relieving for 
women with a history of ICP as it is not associated with their life expectation. In addition, 
there is no need for the health care system to follow-up ICP mothers' health because of 
the nonexistent risk of premature death. 
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Table 1. Median ages and age ranges of the cohort at labour, at death, and those still living at the end of 2015. 
Mothers with ICP Reference group 
n median age age range n median age age range 
At labour 571 27.6 16.9 ─ 41.1 1333 27.1 15.0 ─ 46.4 
At death 39 56.7 34.1 ─ 78.5 111 55.9 28.1 ─ 83.8 
Living at the end of 2015 532 63.7 48.0 ─ 80.8 1222 63.3 46.3 ─ 85.0 
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Figure 1. Survival in the ICP and the control groups regarding age. The censored line indicates the 
subjects who are alive at the end of the follow-up time. 
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Figure 2. Survival in the ICP and the control groups regarding years after labour. The censored line 
indicates the subjects who are alive at the end of the follow-up time. 
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